FMP
Relmada Therapeutics, Inc.
RLMD
NASDAQ
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
0.363 USD
0.0102 (2.81%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Sergio Traversa M.B.A., Pharm.D.
sector
Healthcare
industry
Biotechnology
website
https://www.relmada.comexchange
NASDAQ
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
CIK
0001553643
ISIN
US75955J4022
CUSIP
75955J402
Address
2222 Ponce de Leon Boulevard
Phone
786 629 1376
Country
US
Employee
20
IPO Date
Jun 20, 2014
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
RLMD Financial Summary
CIK
0001553643
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
75955J402
ISIN
US75955J4022
Country
US
Price
0.36
Beta
0.41
Volume Avg.
772.9k
Market Cap
10.95M
Shares
-
52-Week
0.342-7.223
DCF
0.14
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.13
P/B
-
Website
https://www.relmada.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest RLMD News
It looks like there's no news available.
